SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Neotherapeutics Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
640656104
(CUSIP Number)
March 31, 2002
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 640656104 13G Page 2 of 6 Pages
________________________________________________________________________________
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Royal Canadian Growth Fund
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
The jurisdiction of organization is Canada
________________________________________________________________________________
5. SOLE VOTING POWER
N/A
NUMBER OF _________________________________________________________________
SHARES 6. SHARED VOTING POWER
BENEFICIALLY
OWNED BY EACH 2,087,500
REPORTING _________________________________________________________________
PERSON WITH 7. SOLE DISPOSITIVE POWER
N/A
_________________________________________________________________
8. SHARED DISPOSITIVE POWER
2,087,500
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,087,500
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.8%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
OO
________________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1(a) Name of Issuer:
Neotherapeutics Inc.
Item 1(b) Address of Issuer's Principal Executive Offices:
Neotherapeutics Inc.
157 Technology Drive
Irvine, CA 92618
(949) 788-6700
Item 2(a) Name of Person Filing:
Royal Canadian Growth Fund
Item 2(b) Address of Principal Business Office or, if None, Residence:
Royal Canadian Growth Fund
c/o The Royal Trust Company
Royal Trust Tower
77 King Street West, 3rd Floor
Toronto, Ontario M5W 1P9
Item 2(a) Citizenship:
Canada
Item 2(d) Title of Class of Securities:
Common Stock
Item 2(e) CUSIP Number:
640656104
Item 3. If this statement is filed pursuant to Rules 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [_] Broker or dealer registered under Section 15 of the Act (15
U.S.C.78o);
(b) [_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C.78c);
(c) [_] Insurance company as defined in Section 3(a)(19) of the Act (15
U.S.C.78c);
(d) [_] Investment company registered under Section 8 of the Investment
Company Act of 1940 (15 U.S.C.8a-8);
(e) [_] An Investment Adviser in accordance with Section 240. 13d-1(b)(1)
(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance with
Section 240. 13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance with
Section 240. 13d-1(b)(1)(ii)(G);
(h) [_] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i) [_] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C.80a-3);
(j) [_] Group, in accordance with Section 240. 13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Section 240 13d-1(c), check this
box. [X]
Item 4. Ownership.
(a) Amount beneficially owned:
2,087,500
(b) Percent of class:
7.8%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote
N/A
(ii) Shared power to vote or to direct the vote
2,087,500
(iii) Sole power to dispose or to direct the disposition of
N/A
(iv) Shared power to dispose or to direct the disposition of
2,087,500
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [_].
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
The Royal Trust Company, as trustee, has appointed RBC Funds Inc. as
manager of the Royal Canadian Growth Fund ("Fund"), which in turn has delegated
its management duties to RBC Global Investment Management Inc. ("RBC GIM").
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the Group.
N/A
Item 9. Notice of Dissolution of Group.
N/A
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of and do not have the effect of changing or influencing the control of
the issuer of such securities and were not acquired and are not held in
connection with or as a participant in any transaction having such purpose or
effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
April 10, 2002
-------------------------------
(Date)
/s/ Donald L.F. Cant
-------------------------------
(Signature)
Donald L.F. Cant/
Authorized Signatory,
The Royal Trust Company, as
Trustee
-------------------------------
(Name/Title)